Richardson, Paul G.

How I treat multiple myeloma in younger patients

Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 133

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 123

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 114

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsTGF-β signaling in diseases

Cited by 110

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 109

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 104

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

Ghobrial, I. M., Weller, E., Vij, R., Munshi, N. C., Banwait, R., Bagshaw, M., Schlossman, R., Leduc, R., Chuma, S., Kunsman, J., et al. (2011) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 95

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Fabre, C., Mimura, N., Bobb, K., Kong, S.-Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., et al. (2012) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 82

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

Tian, Z., Zhao, J.-J., Tai, Y.-T., Amin, S. B., Hu, Y., Berger, A. J., Richardson, P., Chauhan, D., & Anderson, K. C. (2012) · Blood

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 82

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

Nooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 73

Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group

Samur, M. K., Aktas Samur, A., Fulciniti, M., Szalat, R., Han, T., Shammas, M., Richardson, P., Magrangeas, F., Minvielle, S., Corre, J., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 70

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 70

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Attal, M., Palumbo, A., Holstein, S. A., Lauwers-Cances, V., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Anderson, K. C., Caillot, D., et al. (2016) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 63

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 62

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 49

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 46

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Laubach, J. P., & Richardson, P. G. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 43

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Nadeem, O., Magidson, S., Midha, S., O'Donnell, E. K., Hartley-Brown, M. A., Sperling, A. S., Redd, R. A., Marto, M., Davie, C., Ricciardi, C., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 37

Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma

Lee, M. J., Wickner, P., Fanning, L., Schlossman, R., Richardson, P., Laubach, J., & Castells, M. (2014) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsDrug-Induced Adverse Reactions

Cited by 31

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 20

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 9

Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial (Preprint)

Normann, A. J., Mo, C. C., Wilson, R. L., Perez, M., Cutler, C., Uno, H., Thompson, L. V., Skinner, T. L., Richardson, P. G., Marinac, C. R., et al. (2024) · JMIR Research Protocols

Nutrition and Health in AgingMultiple Myeloma Research and Treatments

Cited by 6